Treatment implications

Alcohol Research and Health

Volumn 31, Issue 4, 2009, Pages 400-407

  Krishnan Sarin, Suchitra ^a   O'Malley, Stephanie ^a   Krystal, John H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acamprosate; Alcohol and other drug dependence; Alcoholism; Animal models; Antipsychotics; Baclofen; Disulfiram; Drug therapy; Human studies; Naltrexone; Neurochemical systems; Neuropharmacology; Ondansetron; Pharmacotherapy; Selective serotonin reuptake inhibitors (SSRIs); Topiramate; Treatment

Indexed keywords

ACAMPROSATE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; NALTREXONE; NARCOTIC ANTAGONIST; TAURINE;

ALCOHOLISM; ANALOGS AND DERIVATIVES; BRAIN CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; BRAIN CHEMISTRY; DISULFIRAM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; TAURINE; TREATMENT OUTCOME;

EID: 84929940209     PISSN: 15357414     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Acheson, A.; Mahler, S.V.; Chi, H.; and De Wit, H. Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology 186(1):54-63, 2006. PMID: 16565827
2. Addolorato, G.; Caputo, F.; Capristo, E.; et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism 37(5):504-508, 2002. PMID: 12217947
3. Addolorato, G.; Leggio, L.; Ferrulli, A.; et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet 370(9603):1915-1922, 2007 PMID: 18068515
4. Anton, R.F.; Kranzler, H.; Breder, C.; et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology 28(1):5-12, 2008b. PMID: 18204334
5. Anton, R.F.; O'Malley, S.S.; Ciraulo, D.A.; et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA Journal of the American Medical Association 295(17):2003-2017, 2006. PMID: 16670409
6. Anton, R.F.; Oroszi, G.; O'Malley, S.; et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 65(2):135-144, 2008a. PMID: 18250251
7. Baldwin, H.A.; Rassnick, S.; Rivier, J.; et al. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103(2):227-232, 1991 PMID: 2027923
8. Barnes, N.M., and Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083-1152, 1999. PMID: 10462127
9. Binneman, B.; Feltner, D.; Kolluri, S.; et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. American Journal of Psychiatry 165(5):617-620, 2008. PMID: 18413705
10. Blomqvist, O.; Hernandez-Avila, C.A.; Van Kirk, J.; et al. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcoholism: Clinical and Experimental Research 26(3):326-331, 2002. PMID: 11923584
11. Bouza, C.; Angeles, M.; Muñoz, A.; and Amate, J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99(7):811-828, 2004. PMID: 15200577
12. Carroll, K.M.; Nich, C.; Ball, S.A.; et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93(5):713-727, 1998. PMID: 9692270
13. Chi, H., and De Wit, H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcoholism: Clinical and Experimental Research 27(5):780-786, 2003. PMID: 12766622
14. Colombo, G.; Addolorato, G.; Agabio, R.; et al. Role of GABA(B) receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotoxicity Research 6(5):403-414, 2004. PMID: 15545024
15. Colombo, G.; Serra, S.; Brunetti, G.; et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology 159(2):181-187, 2002. PMID: 11862347
16. Cornelius, J.R.; Salloum, I.M.; Ehler, J.G.; et al. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Archives of General Psychiatry 54(8):700-705, 1997. PMID: 9283504
17. Czachowski, C.L.; Legg, B.H.; and Samson, H.H. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcoholism: Clinical and Experimental Research 25(3):344-350, 2001. PMID: 11290844
18. Dahchour, A.; De Witte, P.; Bolo, N.; et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Research 82(2):107-114, 1998 PMID: 9754453
19. De Witte, P.; Littleton, J.; Parot, P.; and Koob, G. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs 19(6):517-537, 2005. PMID: 15963001
20. Dyr, W.; Ligieza, J.; and Kostowski, W. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol 42(6):509-512, 2008. PMID: 18504086
21. Egli, M. Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addiction Biology 10(4):309-319, 2005. PMID: 16318951
22. Farook, J.M.; Morrell, D.J.; Lewis, B.; et al. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol and Alcoholism 42(4):296-300, 2007. PMID: 17548369
23. Flannery, B.A.; Garbutt, J.C.; Cody, M.W.; et al. Baclofen for alcohol dependence: A preliminary open-label study. Alcoholism: Clinical and Experimental Research 28(10):1517-1523, 2004. PMID: 15597084
24. Froehlich, J.; O'Malley, S.S.; Hyytiä, P.; et al. Preclinical and clinical studies on naltrexone: What have they taught each other? Alcoholism: Clinical and Experimental Research 27(3):533-539, 2003. PMID: 12658121
25. Fuller, R.K.; Branchey, L.; Brightwell, D.R.; et al. Disulfiram treatment of alcoholism: A Veterans Administration cooperative study. JAMA: Journal of the American Medical Association 256(11): 1449-1455, 1986. PMID: 3528541
26. Garbutt, J.C.; Kranzler, H.R.; O'Malley, S.S.; et al. Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA: Journal of the American Medical Association 293(13):1617-1625, 2005. PMID: 15811981
27. Gass, J.T., and Olive, M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochemical Pharmacology 75(1):218-265, 2008. PMID: 17706608
28. Gelernter, J; Gueorguieva, R.; Kranzler, H.R.; et al. VA Cooperative Study #425 Study Group. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. Alcoholism: Clinical and Experimental Research 31(4):555-563, 2007. PMID: 17374034
29. George, D.T.; Gilman, J.; and Hersh, J.; et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319(5869):1536-1539, 2008. PMID: 18276852
30. Goldstein, M., and Nakajima, K. The effect of disulfiram on catecholamine levels in the brain. Journal of Pharmacology and Experimental Therapeutics 157(1):96-102, 1967. PMID: 6029496
31. Goldstein, M.; Anagnoste, B.; Lauber, E.; and Mckeregham, M.R. Inhibition of dopamine-beta-hydroxylase by disulfiram. Life Sciences 3:763-767, 1964. PMID: 14203977
32. Gorelick, D.A., and Paredes, A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcoholism: Clinical and Experimental Research 16(2):261-265, 1992 PMID: 1317133
33. Gueorguieva, R.; Wu, R.; Pittman, B.; et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biological Psychiatry 61(11):1290-1295, 2007. PMID: 17224132
34. Gulley, J.M.; McNamara, C.; Barbera, T.J.; et al. Selective serotonin reuptake inhibitors: Effects of chronic treatment on ethanol-reinforced behavior in mice. Alcohol 12(3):177-181, 1995. PMID: 7639947
35. Harris, B.R.; Prendergast, M.A.; Gibson, D.A.; et al. Acamprosate inhibits the binding and neuro-toxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism: Clinical and Experimental Research 26(12):1779-1793, 2002. PMID: 12500101
36. Heilig, M., and Koob, G.F. A key role for corti-cotropin-releasing factor in alcohol dependence. Trends in Neurosciences 30(8):399-406, 2007. PMID: 17629579
37. Ingman, K.; Kupila. J.; Hyytiä, P.; and Korpi, E.R. Effects Of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol and Alcoholism 41(4):391-398, 2006. PMID: 16684847
38. Johnson, B.A.; Campling, G.M.; Griffiths, P.; and Cowen, P.J. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: A preliminary study in healthy male volunteers. Psychopharmacology 112(1):142-144, 1993. PMID: 7871004
39. Johnson, B.A.; Roache, J.D.; Javors, M.A.; et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA: Journal of the American Medical Association 284(8):963-971, 2000. PMID: 10944641
40. Johnson, B.A.; Rosenthal, N.; Capece, J.A.; et al. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Archives of Internal Medicine 168(11):1188-1199, 2008. PMID: 18541827
41. Kampman, K.M.; Pettinati, H.M.; Lynch, K.G.; et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. Journal of Clinical Psychopharmacology 27(4):344-351, 2007. PMID: 17632217
42. Kranzler, H.R., and Gage, A. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials. American Journal on Addictions 17(1):70-76, 2008. PMID: 18214726
43. Kranzler, H.R.; Burleson, J.A.; Korner, P.; et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 152(3):391-397, 1995. PMID: 7864265
44. Kranzler, H.R.; Burleson, J.A.; Brown, J.; and Babor, T.F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism: Clinical and Experimental Research 20(9):1534-1541, 1996. PMID: 8986200
45. Kranzler, H.R.; Pierucci-Lagha, A.; Feinn, R.;and Hernandez-Avila, C. Effects of ondansetron in early-versus late-onset alcoholics: A prospective, open-label study. Alcoholism: Clinical and Experimental Research 27(7):1150-1155, 2003. PMID: 12878921
46. Kranzler, H.R.; Mueller, T.; Cornelius, J.; et al. Sertraline treatment of co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology 26(1):13-20, 2006. PMID: 16415699
47. Kranzler, H.R.; Covault, J.; Pierucci-Lagha, A.; et al. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcoholism: Clinical and Experimental Research 32(4):573-579, 2008. PMID: 18261195
48. Krishnan-Sarin, S.; Krystal, J.H.; Shi, J.; et al. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biological Psychiatry 62(6):694-697, 2007. PMID: 17336941
49. Krupitsky, E.M.; Rudenko, A.A.; Burakov, A.M.; et al. Antiglutamatergic strategies for ethanol detoxification: Comparison with placebo and diazepam. Alcoholism: Clinical and Experimental Research 31(4): 604-611, 2007. PMID: 17374039
50. Krystal, J.H.; Cramer, J.A.; Krol, W.F.; et al. Veterans Affairs Naltrexone Cooperative Study 425 Group: Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 345(24): 1734-1739, 2001. PMID: 11742047
51. Lê, A.D.; Wang, A.; Harding, S.; et al. Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. Psychopharmacology 168(1-2): 216-221, 2003. PMID: 12536264
52. Littleton, J., and ZieglgäNsberger, W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. American Journal on Addictions 12 (Suppl. 1) :S3-S11, 2003. PMID: 14972776
53. LöF, E.; Olausson, P.; deBejczy, A.; et al. Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology 195(3):333-343, 2007. PMID: 17703283
54. Lovinger, D.M., and Crabbe, J.C. Laboratory models of alcoholism: Treatment target identification and insight into mechanisms. Nature Neuroscience 8(11): 1471-1480, 2005. PMID: 16251990
55. Marinelli, P.W.; Quirion, R.; Gianoulakis, C. A microdialysis profile of beta-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology 169(1): 60-67, 2003. PMID: 12759807
56. Mason, B.J.; Goodman, A.M; Chabac, S.; and Lehert, P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. Journal of Psychiatric Research 40(5):383-393, 2006. PMID: 16546214
57. Mann, K.; Lehert, P.; and Morgan, M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcoholism: Clinical and Experimental Research 28(1):51-63, 2004. PMID: 14745302
58. McKee, S.A.; O'Malley, S.S.; Shi, J.; et al. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology 196(2):189-200, 2008. PMID: 17912500
59. Monnelly, E.P.; Ciraulo, D.A.; Knapp, C.; et al. Quetiapine for treatment of alcohol dependence. Journal of Clinical Psychopharmacology 24(5):532-535, 2004. PMID: 15349010
60. Myers, R.D., and Veale, W.L. Alcohol preference in the rat: Reduction following depletion of brain serotonin. Science 160(835):1469-1471, 1968. PMID: 5690148
61. Naassila, M.; Pierrefiche, O.; Ledent, C.; and Daoust, M. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology 46(2):243-253, 2004. PMID: 14680762
62. Naranjo, C.A.; Bremner, K.E.; and Lanctôt, K.L. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90(1):87-99, 1995. PMID: 7888983
63. Nguyen, S.A.; Malcolm, R.; and Middaugh, L.D. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 61(3):150-156, 2007. PMID: 17146766
64. O'Malley, S.S.; Jaffe, A.J.; Chang, G.; et al. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 49(11):881-887, 1992. PMID: 1444726
65. O'Malley, S.S.; Krishnan-Sarin, S.; Farren, C.; et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160(1):19-29, 2002. PMID: 11862370
66. Oslin, D.W.; Berrettini, W.; Kranzler, H.R.; et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8):1546-1552, 2003. PMID: 12813472
67. Petrakis, I.L.; Poling, J.; Levinson, C.; et al. VA New England VISN I MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry 57(10):1128-1137, 2005. PMID: 15866552
68. Pettinati, H.M.; Volpicelli, J.R.; Kranzler, H.R.; et al. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcoholism: Clinical and Experimental Research 24(7):1041-1049, 2000. PMID: 10924008
69. Reilly, M.T.; Lobo, I.A.; McCracken, L.M.; et al. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcoholism: Clinical and Experimental Research 32(2):188-196, 2008. PMID: 18226119
70. Shapiro, D.A.; Renock, S.; Arrington, E.; et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400-1411,2003.PMID: 12784105
71. Sinha, R. The role of stress in addiction relapse. Current Psychiatry Reports 9(5):388-395, 2007 PMID: 17915078
72. Slawecki, C.J.; Jimenéz-Vasquez, P.; Mathé, A.A.; and Ehlers, C.L. Substance P and neurokinin levels are decreased in the cortex and hypothalamus of alcohol-preferring (P) rats. Journal of Studies on Alcohol 62(6):736-740, 2001 PMID: 11838908
73. Soyka, M.; Koller, G.; Schmidt, P.; et al. ACTOL Study Investigators. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Journal of Clinical Psychopharmacology 28(3):317-324, 2008. PMID: 18480689
74. Spanagel, R.; Putzke, J.; Stefferl, A.; et al. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. European Journal of Pharmacology 305(1-3):45-50, 1996. PMID: 8813530
75. Srisurapanont, M., and Jarusuraisin, N. Opioid antagonists for alcohol dependence. Cochrane Database System Reviews (2):CD001867, 2002. PMID: 12076425
76. Steensland, P.; Simms, J.A.; Holgate, J.; et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America 104(30):12518-12523, 2007. PMID: 17626178
77. Swift, R.M. Opioid antagonists and alcoholism treatment. CNS Spectrums 5(2):49-57, 2000. PMID: 18296998
78. Swift, R.M.; Davidson, D.; Whelihan, W.; and Kuznetsov, O. Ondansetron alters human alcohol intoxication. Biological Psychiatry 40(6):514-521, 1996. PMID: 8879472
79. Valdez, G.R.; Roberts, A.J.; Chan, K.; et al. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: Regulation by corticotropin-releasing factor. Alcoholism: Clinical and Experimental Research 26(10):1494-1501, 2002 PMID: 12394282
80. Verheul, R.; Lehert, P.; Geerlings, P.J.; et al. Predictors of acamprosate efficacy: Results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 178(2-3):167-173, 2005. PMID: 15322728
81. Volpicelli, J.R.; Alterman, A.I.; Hayashida, M.; and O'Brien, C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49(11):876-880, 1992. PMID: 1345133
82. Zalewska-Kaszubska, J.; Gorska, D.; Dyr, W.; and Czarnecka, E. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacology, Biochemistry, and Behavior 85(1):155-159, 2006. PMID: 16934320